Monday report

“Simplicity is a great virtue but it requires hard work to achieve it and education to appreciate it. And to make matters worse: complexity sells better.”
– Edsger W. Dijkstra

From Washington, DC.

  • The American Hospital Association News reports,
    • “In comments provided Nov. 16 to majority and minority leaders of the House and Senate, the AHA requested Congress to act on key priorities for hospitals and health systems before the end of 2026. The AHA urged Congress to extend healthcare programs set to expire at the end of the year, including the Medicare-dependent Hospital and the Low-volume Adjustment programs, the work geographic practice cost index floor, the clinical laboratory fee schedule, the National Health Service Corps, the Conrad State 30 Program and the Cybersecurity Information Sharing Act of 2015. The AHA also recommended Congress provide protections for the 340B Drug Pricing Program, stabilize and maintain access to long-term care hospitals, reject site-neutral payment expansions and improve insurer accountability.”
  • and
    • “The Department of Labor released an enforcement alert Nov. 13 to employers and health plan fiduciaries to ensure that plan participants and beneficiaries are receiving accurate provider directories for in-network coverage. The department said the alert stemmed from a secret shopper survey conducted by the Employee Benefits Security Administration, which contacted 27,000 providers across 27 networks and found that 36% of directories had incorrect information. The alert includes best practices and questions to ask providers on how they maintain and update their directories.” 
  • Per a Department of Health and Human Services news release,
    • “The U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) today announced a Final Rule, HIPAA Privacy Rule: Changes to Support Coordinated Care and Individual Engagement and Reduce Regulatory Burdens. This final rule strengthens individuals’ rights to access their own protected health information (PHI), including electronic PHI through personal health apps; improves information sharing for care coordination and case management; and reduces regulatory and administrative burdens on covered entities.
    • * * * “The final rule includes the following modifications to the Privacy Rule:
    • “Strengthens the Individual Right of Access
      • “Reduces the amount of time that covered entities have to respond to individuals’ requests for copies of their PHI.
      • “Establishes that the individual right of access includes the right of an individual to obtain a copy of their electronic PHI through a personal health app when the covered entity has the capability to produce the PHI in that form and format.
      • “Amends the permissible fees for responding to right of access requests, including by establishing when copies of PHI must be provided to the individual for free, and requires advance notice of fees.
      • “Implements the right of access to direct a covered entity to transmit an electronic copy of PHI in an electronic health record to a person designated by the individual.
      • “Reduces the burden of identity verification on individuals exercising their access rights.
    • “Facilitates Care Coordination
      • “Clarifies that health plans may use and disclose PHI for care coordination and case management for individuals and expressly permits covered entities to disclose PHI to social services agencies, community-based organizations, and similar third parties for care coordination and case management for individuals.
    • “Reduces Regulatory Burdens
      • “Eliminates requirement to make a good faith effort to obtain from individuals written acknowledgment of receipt of a Notice of Privacy Practices.
      • “Permits disclosures to Telecommunications Relay Services (TRS) communications assistants for persons who are deaf, hard of hearing, or deaf-blind, or who have a speech disability, and excludes TRS providers from the definition of business associate.
      • “Permits certain disclosures of PHI of United States Public Health Service and National Oceanic and Atmospheric Administration Commissioned Corps personnel to command authorities for mission readiness, expanding on a previous permission that applied only to the Armed Forces.
    • “This final rule is effective 60 days after publication. The Final Rule may be viewed here: https://www.federalregister.gov/public-inspection/2026-23429/hipaa-privacy-rule-changes-to-support-coordinated-care-and-individual-engagement-and-reduce
    • “View The Final Rule Fact Sheet here: https://www.hhs.gov/hipaa/for-professionals/privacy/changes-support-coordinated-care-individual-engagement-reduce-regulatory-burdens-final-rule.html.”
  • Federal New Network relates,
    • “The White House is pushing for a top Office of Management and Budget official to be the next leader of the Government Accountability Office, setting up a lame duck battle over the future of the Congressional watchdog.
    • “President Donald Trump on Monday formally nominated OMB Deputy Director Eric Ueland to serve as the next comptroller general. Ueland also served in the first Trump administration. A former Senate staffer, he has been instrumental in the second Trump administration’s efforts to reshape the federal bureaucracy.
    • “Ueland’s nomination comes after Senate Homeland Security and Governmental Affairs Committee Chairman Rand Paul (R-Ky.) cleared a path for the White House to name a comptroller general nominee without getting bipartisan input from Congress.
    • “Paul has scheduled a Thursday hearing for Ueland, along with nine other nominees.”
  • Per a National Institutes of Health news release,
    • “National Institutes of Health (NIH) Director Jay Bhattacharya, M.D., Ph.D., today announced the selection of John H. Powers III, M.D., as director of NIH’s National Institute of Allergy and Infectious Diseases (NIAID). Dr. Powers currently serves as NIAID Acting Director and Principal Deputy Director and as an infectious diseases attending physician for the institute in the NIH Clinical Center. NIAID conducts and supports basic and applied research to better understand, treat and ultimately prevent infectious, immunologic and allergic diseases.  
    • “Dr. Powers is a physician-scientist who has spent more than three decades caring for patients, teaching and mentoring the next generation of investigators, and playing an integral role in research that improves lives. He has been a trusted and valued colleague within NIAID for several decades, and will bring a focus on rigor, transparency, and research outcomes to leading the institute into the future.,” said Dr. Bhattacharya. “I am thankful for his commitment to serve and glad to permanently welcome him to the NIH leadership team.” 

From the U.S. Office of Personnel Management front,

  • Federal News Network offers an interview with Shelly Giuliano about how to shop for a health plan during the ongoing Open Season.
  • Kevin Moss, writing in Federal News Network, points out that
    • “One of the most significant changes in Federal Employees Health Benefits next year is centered around GLP-1 prescription drugs. Their popularity is growing fast: Roughly one in eight U.S. adults now takes a GLP-1 for weight loss or to help manage a chronic condition. Spending has climbed even faster. For the two carriers that represent 69% of FEHB members, an Office of Personnel Management inspector general report found GLP-1 spending rose more than 500%, from $392 million in 2019 to $2.6 billion in 2024.
    • “In response to these rising costs, OPM has introduced a new prior-authorization requirement for everyone in any FEHB plan who receives a GLP-1 prescribed for weight loss. Most carriers have also raised the cost-share to 50%.
    • “I’ll share all the details about these changes plus ways federal employees and annuitants can save money on GLP-1s next year.”

From the U.S. Food and Drug Administration front,

  • STAT News reports,
    • “The Food and Drug Administration on Monday approved a new breast cancer drug from Roche, teeing up the launch of a medicine that the Swiss company has said could become its top-selling product ever.
    • “The approval of Wilserdly, also known as giredestrant, was one of the most important regulatory decisions Roche had been awaiting. It also gives the company another foothold in breast cancer treatments, a field in which it has a storied history with the drug Herceptin through its subsidiary Genentech, though in recent years it’s fallen behind rival pharma companies in oncology. 
    • “The approval is specifically for patients with HR-positive, HER2-negative advanced breast cancer that has picked up a mutation in the ESR1 gene, a sign that the tumor is developing resistance to standard treatments. The evERA trial showed that the drug, an oral treatment known as a selective estrogen receptor degrader, or SERD, extended the time period before patients’ tumors progressed.”
  • and
    • “The Food and Drug Administration is proposing a new classification for a product that’s existed in a legal gray area for years, a win for proponents of dietary supplements, including members of the MAHA movement. 
    • “The proposed rule would classify N-acetyl-L-cysteine, known as NAC and already widely sold over the counter, as the agency’s first “Dietary Ingredient Not Excluded from the Dietary Supplement Definition” — in essence, not not a supplement. 
    • “The need for the legal backbending stems from the fact that the FDA previously approved NAC as a drug, and FDA regulations prohibit the agency from including approved drugs in the dietary supplement category. In 1963, the agency approved NAC to break up mucus in certain lung conditions, and in 1985 to treat acetaminophen overdose.” 
  • Beckers Hospital Review relates,
    • The FDA has rejected Summit Therapeutics’ application for ivonescimab for certain patients with advanced lung cancer after the treatment did not show a statistically significant improvement in overall survival.
    • “Summit said the FDA cited the finding in rejecting the drug, according to a Nov. 15 news release. The application sought approval of ivonescimab with platinum-containing chemotherapy for patients with locally advanced or metastatic EGFR-mutated non-squamous non-small cell lung cancer who had previously received a third-generation EGFR-targeted therapy. The FDA issued a complete response letter, saying substantial evidence of effectiveness was not established without a statistically significant overall survival improvement. The agency’s decision date was Nov. 14.”
  • Per Fierce Pharma,
    • As Roche’s Gazyva comes under pressure in blood cancer, the anti-CD20 antibody keeps expanding its reach in autoimmune diseases.
    • In its third U.S. indication for an immune-mediated condition, Gazyva has become the first FDA-approved treatment for primary membranous nephropathy (pMN), a rare disease where the immune system mistakenly attacks the tiny filtering units in the kidneys.
    • The drug is specifically approved to reduce proteinuria, or the abnormal presence of protein in the urine, which is a key indicator of kidney damage.
  • Radiology Business tells us,
    • “The U.S. Food and Drug Administration has cleared a new imaging artificial intelligence software for brain aneurysm detection, the product’s developers announced Friday. 
    • “Uptunity was designed to support radiologists and other physicians in spotting signs of this clinical concern on CT angiography, along with aiding in follow-up assessments. The software was developed by contrast-agent manufacturer Bracco in collaboration with Avicenna.AI. 
    • “The two note that 1 in every 50 U.S. adults suffer an unruptured brain aneurysm, a condition that is often asymptomatic and difficult to detected on images. 
    • “A small incidental aneurysm on a head CTA can easily be overlooked when the work list keeps growing,” Cosimo DePinto, executive VP of marketing and commercial operations for Bracco Americas, said in a statement Nov. 13. “Uptunity Aneurysm works inside the reading environment radiologists already know and helps find the aneurysm hiding in the CT scan. The clinical decision stays where it belongs: with the radiologist.”
  • MedTech Dive informs us,
    • “MiniMed received Food and Drug Administration clearance for its first tubeless insulin pump, the company said on Monday. 
    • “The device, called MiniMed Fit, can be worn for up to seven days and has an insulin capacity of 300 units. It’s cleared for people with Type 1 and Type 2 diabetes ages seven and older.
    • “MiniMed will compete with market leader Insulet and Tandem Diabetes Care, which just debuted its first tubeless pump, giving people with diabetes more options.”

From the fraud, waste, and abuse front,

  • Per a Centers for Medicare and Medicaid Service news release,
    • “The Centers for Medicare & Medicaid Services (CMS), a division of the U.S. Department of Health and Human Services (HHS), today issued a proposed rule that could save taxpayers nearly $90 billion over the next 10 years and would strengthen program integrity (PI) oversight and the agency’s ability to prevent, identify, and address fraud, waste, and abuse across Medicare, Medicaid, the Children’s Health Insurance Program (CHIP), and the Health Insurance Marketplace.
    • “The Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) proposed rule is a standalone, discretionary rule that proposes changes to strengthen program integrity by enhancing provider screening and enrollment safeguards, requiring prompt self-reporting and return of identified fee-for-service overpayments, improving managed-care program-integrity reporting to better oversee potential fraud and improper payments, increasing provider-ownership transparency and data reporting for oversight agencies, and intensifying scrutiny of deductions from Medicaid payments.” * * *
    • “CRUSH would advance the Trump Administration’s commitment to making fraud prevention a core responsibility across federal healthcare programs. Building on stakeholder input and record program integrity results, the proposal would strengthen CMS’ ability to intervene earlier, hold providers and plans accountable, and protect coverage and care for millions of Americans.
    • “CMS encourages public comment on the proposed rule. Comments are due Jan. 19, 2027.
    • “The proposed rule is available in the Federal Register at: https://public-inspection.federalregister.gov/2026-23461.pdf [PDF]
    • “View the proposed rule fact sheet at: https://www.cms.gov/newsroom/fact-sheets/comprehensive-regulations-uncover-suspicious-healthcare-crush-proposed-rule-cms-6098-p“

From the public health and medical / Rx research front,

  • Beckers Clinical Leadership reports,
    • “When the Pan American Health Organization confirmed Nov. 14 the U.S. lost the measles elimination status it held since 2000, Michael Osterholm, PhD, was not surprised.
    • “Many of us believe that we had lost our elimination status many months ago,” said Dr. Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota in Minneapolis. “So to me, this was much more about a technical definition than it was about a reality. The reality was we’ve been in big trouble with measles in this country for months.”
    • “As of Nov. 12, the CDC had recorded 5,412 measles cases this year across 46 states and the District of Columbia, with 11% of patients hospitalized. Dr. Osterholm told Becker’s [in this article] what the shift means for hospitals and what it would take to reverse it.”
  • The American Medical Association tells us what doctors ants patients to know about joint replacements.
    • “Joint replacement is no longer just for older adults. Here’s what every patient needs to know about surgery, implant longevity, recovery and revision.”
  • The New York Times explains why “Why a Little Extra Weight May Benefit Older People.
    • “Even in the age of obesity drugs, researchers say many don’t need to shed pounds.”
  • FEHBlog observation – A dietician once told me that while people should avoid an obese BMI, an overweight BMI is acceptable for seniors because if a senior contracts an acute illness, he or she is likely to lose weight which is hard to put back on.
  • The Wall Street Journal informs us,
    • “Novo Nordisk showed its drug Wegovy helped children age 6 to 11 with obesity lose weight, though they grew more slowly on average than peers.
    • “In a study of adolescents, Eli Lilly’s drug Zepbound reduced body-mass index by an average of 18.5%.
    • “Both drugs improved other health markers like blood sugar and some measures of cholesterol.” 
  • Health Day lets us know,
    • “An erratic sleep schedule can contribute to mood disorders
    • “People with irregular sleep and wake times had higher levels of anxiety, depression and loneliness
    • “As little as a half hour additional variation in sleep can impact mood.”
  • Healio adds,
    • “A study projected a 10-year jump in median age for people with HIV by 2040.
    • “This shifting demographic will present new challenges for healthcare.”
  • STAT News relates,
    • “A cancer immunotherapy from CG Oncology delivered into the bladders of patients reduced the risk of tumor recurrence by 68% compared to current medical practice — positive study results announced Monday that may change the way physicians treat certain patients with bladder cancer.
    • “The CG Oncology treatment, called cretostimogene, is made from a type of common cold virus engineered to target cells that express a specific mutation found in bladder tumors. Physicians use a catheter to infuse “creto” directly into the bladder, where it enters the mutated cancer cells, replicates rapidly, then breaks open the cells, killing them.” * * *
    • “On Monday, the company said it was delaying its submission to the Food and Drug Administration until March 2027 in order to incorporate new clinical data that could lead to an approval encompassing a larger proportion of these high-risk patients. 
    • “Previously, CG Oncology had said its initial FDA submission for high-risk bladder cancer would be completed by the end of the year. 
    • “We’re just shifting by three months, and we’re gonna own the March date that we feel confident in,” said CG Oncology CEO Arthur Kuan. 
    • “Discussions with the FDA about how to best seek approval of creto to treat intermediate-risk bladder cancer remain ongoing, Kuan added.” 
  • Beckers Hospital Review notes,
    • “Active U.S. drug shortages stood at 225 at the end of the third quarter, similar to the past three quarters, according to the American Society of Health-System Pharmacists. The 87 new shortages reported through September nearly equal the 89 reported for all of 2025, and chemotherapy shortages in particular have outlasted drugmakers’ resupply estimates. The FDA’s database continues to reflect new discontinuations weekly.
    • “The article identifies] six recent shortage and discontinuation listings, according to the FDA database.”

From the U.S. healthcare business and artificial intelligence front,

  • MedCity News reports,
    • “Many health technologies develop without input from the end users they’re meant to serve: clinicians and frontline medical workers. Now, The Permanente Medical Group (TPMG), the country’s largest physician-led medical group and part of Kaiser Permanente, is putting those clinicians in the driver’s seat of healthcare innovation. 
    • “TPMG, part of Kaiser Permanente, announced Monday the launch of Permanentech, a new physician-led healthcare innovation company designed to turn frontline clinical insights into technology products, partnerships, and independent businesses.
    • “The announcement, made during the annual HLTH conference in Las Vegas, offers a different approach to healthcare innovation: rather than developing technology in isolation and then trying to persuade clinicians to adopt it, Permanentech intends to put physicians at the center of the process.” 
  • Healthcare Dive adds,
    • “Healthcare remains the AI industry’s biggest vertical, with health AI investments ballooning to $3.7 billion — more than double the past year, according to a new Menlo Partners report.
    • “Provider organizations are looking to deploy AI in new areas, with the most popular ones being front-office operations and clinical copilots, the report shows.
    • “Even though established health IT companies continue to dominate the ambient scribing space, providers are increasingly turning to startups for AI-driven clinical and administrative tools.”
  • and
    • “GLP-1s for weight loss, diabetes and other conditions can save employers and other payers money — if they’re priced at $350 per month or less, according to a new analysis by CVS Health.
    • “The white paper, released Sunday during the HLTH conference in Las Vegas, found that GLP-1s are associated with better health outcomes, fewer hospitalizations and lower medical spending. But at their current sky-high prices, pharmacy spending on GLP-1s swamps any medical savings for plan sponsors, CVS found. Per the Employee Benefit Research Institute, employers typically pay between $617 and $766 a month for GLP-1s.
    • “The goal of the white paper is to pressure drugmakers like Eli Lilly and Novo Nordisk to lower the cost of the popular medications, according to Dr. Amy Compton-Phillips, CVS’ chief medical officer.”
  • Beckers Hospital Review lets us know,
    • “Cleveland Clinic recorded operating income of $326.6 million (6.5% operating margin) during the third quarter of 2026, up from operating income of $206.2 million (4.5% margin) during the same period last year, according to its Nov. 16 financial report.”
  • and
    • “Minnesota Attorney General Keith Ellison’s office entered into a 10-year oversight agreement with Sacramento, Calif.-based Sutter Health and Minneapolis-based Allina Health, completing its review of Allina’s plan to join Sutter.
    • “Mr. Ellison said Nov. 16 that the deal meets the public interest standard under Minnesota’s healthcare transaction law. His office does not approve such deals, but it can seek court relief if it later finds the transaction is no longer in the public interest. The review included two public meetings and more than 675 written comments.”
  • The Wall Street Journal relates,
    • “Eli Lilly has agreed to acquire Calytrix Bio for up to $1.5 billion.
    • “The purchase price includes an undisclosed upfront payment, along with clinical and regulatory milestone payments.
    • “Calytrix Bio is developing therapies aimed at myeloproliferative neoplasms, which are a group of rare blood cancers.”
  • and
    • “Johnson & Johnson JNJ has agreed to buy Ollin Biosciences, a clinical-stage biopharmaceutical company developing therapies for serious eye diseases, for an initial $2.2 billion, and has struck a deal with asset manager Blackstone to fund development of Ollin’s lead asset.
    • “J&J on Monday said the Ollin deal, which includes more than $1.12 billion in potential regulatory and commercial milestone payments, adds OLN324, an investigational bispecific antibody for retinal vascular diseases, including wet age-related macular degeneration and diabetic macular edema.”
  • Here’s a link to Fierce Healthcare’s HLTH Conference tracker.

Leave a Reply

Your email address will not be published. Required fields are marked *